These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 19385971)
1. Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells. Meng X; Li M; Wang X; Wang Y; Ma D Cancer Sci; 2009 Jun; 100(6):1040-6. PubMed ID: 19385971 [TBL] [Abstract][Full Text] [Related]
2. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. Cui F; Wang J; Chen D; Chen YJ Oncol Rep; 2011 Mar; 25(3):701-8. PubMed ID: 21174061 [TBL] [Abstract][Full Text] [Related]
3. More than 45% of A549 and H446 cells are cancer initiating cells: evidence from cloning and tumorigenic analyses. Meng X; Wang X; Wang Y Oncol Rep; 2009 Apr; 21(4):995-1000. PubMed ID: 19287999 [TBL] [Abstract][Full Text] [Related]
4. [Investigation of CD133 as putative marker of tumor-initiating cell in laryngeal carcinoma]. Wei XD; Zhou L; Cheng L; Tian J Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Sep; 42(9):692-6. PubMed ID: 18051573 [TBL] [Abstract][Full Text] [Related]
5. Biologic characteristics of the side population of human small cell lung cancer cell line H446. Wang B; Yang H; Huang YZ; Yan RH; Liu FJ; Zhang JN Chin J Cancer; 2010 Mar; 29(3):254-60. PubMed ID: 20193106 [TBL] [Abstract][Full Text] [Related]
6. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Tirino V; Camerlingo R; Franco R; Malanga D; La Rocca A; Viglietto G; Rocco G; Pirozzi G Eur J Cardiothorac Surg; 2009 Sep; 36(3):446-53. PubMed ID: 19464919 [TBL] [Abstract][Full Text] [Related]
7. Clinical and biological significance of stem-like CD133(+)CXCR4(+) cells in esophageal squamous cell carcinoma. Lu C; Xu F; Gu J; Yuan Y; Zhao G; Yu X; Ge D J Thorac Cardiovasc Surg; 2015 Aug; 150(2):386-95. PubMed ID: 26092504 [TBL] [Abstract][Full Text] [Related]
8. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. Leung EL; Fiscus RR; Tung JW; Tin VP; Cheng LC; Sihoe AD; Fink LM; Ma Y; Wong MP PLoS One; 2010 Nov; 5(11):e14062. PubMed ID: 21124918 [TBL] [Abstract][Full Text] [Related]
9. Characterization of sphere-forming cells with stem-like properties from the small cell lung cancer cell line H446. Qiu X; Wang Z; Li Y; Miao Y; Ren Y; Luan Y Cancer Lett; 2012 Oct; 323(2):161-70. PubMed ID: 22521544 [TBL] [Abstract][Full Text] [Related]
10. Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype. Srivastava VK; Nalbantoglu J Cytometry A; 2008 Oct; 73(10):940-8. PubMed ID: 18773455 [TBL] [Abstract][Full Text] [Related]
11. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Salnikov AV; Gladkich J; Moldenhauer G; Volm M; Mattern J; Herr I Int J Cancer; 2010 Feb; 126(4):950-8. PubMed ID: 19676044 [TBL] [Abstract][Full Text] [Related]
12. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Bertolini G; Roz L; Perego P; Tortoreto M; Fontanella E; Gatti L; Pratesi G; Fabbri A; Andriani F; Tinelli S; Roz E; Caserini R; Lo Vullo S; Camerini T; Mariani L; Delia D; Calabrò E; Pastorino U; Sozzi G Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16281-6. PubMed ID: 19805294 [TBL] [Abstract][Full Text] [Related]
13. CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin. Friedman S; Lu M; Schultz A; Thomas D; Lin RY PLoS One; 2009; 4(4):e5395. PubMed ID: 19404394 [TBL] [Abstract][Full Text] [Related]
14. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. Zito G; Richiusa P; Bommarito A; Carissimi E; Russo L; Coppola A; Zerilli M; Rodolico V; Criscimanna A; Amato M; Pizzolanti G; Galluzzo A; Giordano C PLoS One; 2008; 3(10):e3544. PubMed ID: 18958156 [TBL] [Abstract][Full Text] [Related]
15. Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. Kubo T; Takigawa N; Osawa M; Harada D; Ninomiya T; Ochi N; Ichihara E; Yamane H; Tanimoto M; Kiura K Cancer Sci; 2013 Jan; 104(1):78-84. PubMed ID: 23066953 [TBL] [Abstract][Full Text] [Related]
16. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. Chen YC; Hsu HS; Chen YW; Tsai TH; How CK; Wang CY; Hung SC; Chang YL; Tsai ML; Lee YY; Ku HH; Chiou SH PLoS One; 2008 Jul; 3(7):e2637. PubMed ID: 18612434 [TBL] [Abstract][Full Text] [Related]
17. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116. Dittfeld C; Dietrich A; Peickert S; Hering S; Baumann M; Grade M; Ried T; Kunz-Schughart LA Radiother Oncol; 2009 Sep; 92(3):353-61. PubMed ID: 19699546 [TBL] [Abstract][Full Text] [Related]
18. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy. Liu J; Mao Z; Huang J; Xie S; Liu T; Mao Z Biochem Biophys Res Commun; 2014 Feb; 444(4):670-5. PubMed ID: 24502949 [TBL] [Abstract][Full Text] [Related]
19. TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction. Tirino V; Camerlingo R; Bifulco K; Irollo E; Montella R; Paino F; Sessa G; Carriero MV; Normanno N; Rocco G; Pirozzi G Cell Death Dis; 2013 May; 4(5):e620. PubMed ID: 23640462 [TBL] [Abstract][Full Text] [Related]
20. Differential effects of mesenchymal stem cells on a heterogeneous cell population within lung cancer cell lines. Luo D; Yan X; Liu D; Zhou X; Liu G Mol Cell Biochem; 2013 Jun; 378(1-2):107-16. PubMed ID: 23456479 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]